EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration By Ogkologos - October 3, 2025 292 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns treatment of patients with resectable locally advanced head and neck squamous cell carcinoma Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo... June 10, 2025 Cabozantinib Improves PFS in Patients with Previously Treated, Progressive Advanced Extrapancreatic... October 25, 2024 New on NCI’s Websites for October 2019 October 3, 2019 Adding Tremelimumab to Durvalumab and Chemotherapy Provides Survival Benefit for Patients... November 15, 2022 Load more HOT NEWS FDA Grants Accelerated Approval to Sacituzumab Govitecan for Advanced Urothelial Cancer New Study Shows Intermittent Fasting May Reduce Breast Cancer Risk and... Teacher Battling Cancer Gifted Free School Supplies Mom Fighting Breast Cancer Says Her Haunted House Is Something To...
